摘要
目的 探讨米托蒽醌、长春地辛、地塞米松联合沙利度胺 （MODT方案） 治疗多发性骨髓瘤（MM）的疗效和不良反应.方法 回顾性分析我院2001年10月至2009年2月收治的22例MM患者接受MODT方案治疗的疗效和不良反应.结果 全组患者总有效率为68.2%（15/22）,在新诊断MM组有效率为83.3%（10/12）,而复发或疾病进展组有效率为50.0%（5/10）,2组有效率相比差异无统计学意义（P=0.17）;全组不良反应较多,以1、2级不良反应为主,3、4级不良反应9例次,给予适当处理后均能耐受治疗.结论 MODT方案可取得传统VAD方案相似的疗效和较轻的不良反应,可作为经济条件欠佳的MM患者初始诱导和部分难治患者的挽救治疗,且不影响患者干细胞的动员和采集.
Objective To explore the efficacy and toxicity of MODT （mitozantrone,vindesine,dexamethasone,thalidomide） in the treatment of multiple myeloma（MM）.Methods Twenty-two patients treated in our hospital from October,2001 to Febrary,2009 were recruited in the study.Retrospective analysis of efficacy and toxicity were performed on the data of all patients who received 2-4 cycles of MODT regimen.Results The overall effective rate was 68.2%（15/22）.The effective rate was 83.3%（10/12） in the newly diagnosed group,which was not different from that of 50.0%（5/10） in the recurrent or advanced group （P=0.17）.The adverse responses in all patients were common,and most were I and Ⅱ degree.Adverse responses of Ⅲ and Ⅳ degree occurred in 9 patients,which,were all tolerable after proper treatment.Conclusions The MODT regimen,with lower toxicity,results in the same efficacy as the conventional VAD.It has no effect on stem cell priming and collection and should be considered as the front line therapy in initial MM patients with poor economic conditions.
出处
《中国综合临床》
2010年第4期359-361,共3页
Clinical Medicine of China
